Indefinite Delivery Contract 36C24826D0020

Cepheid Inc., headquartered in Sunnyvale, California, was awarded a single-award Indefinite Delivery Contract by the Department of Veterans Affairs Veterans Integrated Service Network 8 (VISN 8) on April 1, 2026, with a contract ceiling value of $3.5 million and ultimate completion date of September 30, 2029. This civilian agency procurement carries no set-aside designation and establishes an indefinite quantity framework for the supply of Cepheid GeneXpert reagents and supplies. The contract supports the VA's molecular diagnostic testing requirements across VISN 8 medical facilities, enabling on-demand procurement of diagnostic reagents designed for use with existing GeneXpert Infinity systems already in place at VA healthcare locations.

The solicitation, posted as a pre-solicitation notice on December 18, 2025, with a due date of January 9, 2026, was structured as a sole-source procurement reflecting the government's determination that Cepheid represents the only authorized provider capable of supplying compatible reagents for the GeneXpert Infinity platform. The procurement encompasses an extensive catalog of molecular diagnostic tests including assays for methicillin-resistant Staphylococcus aureus, Clostridioides difficile toxin, carbapenem-resistant enterobacteria, chlamydia/gonorrhea, Group A Streptococcus, SARS-CoV-2, influenza, respiratory syncytial virus, and vaginal infection detection. The Indefinite Delivery Indefinite Quantity contract structure allows VISN 8 to place delivery orders on an as-needed basis to support ongoing clinical laboratory operations and infectious disease testing across its distributed network of medical centers, with pricing established on a firm fixed-price basis to ensure budget predictability for the VA healthcare system.